[18F]F-AraG Tracer for Specific Brown Adipose Tissue Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PET imaging agents, such as 2-[F18]fluoro-2-deoxy-D-glucose (FDG), lack specificity for imaging the activation and deactivation of brown adipose tissue (BAT), making it difficult to assess therapeutic effects on BAT.
Innovation Solution
The use of [18F]-F-arabinofuranosyl guanine ([18F]F-AraG) as a PET imaging agent, which can be phosphorylated and trapped in adipose tissue cells, allowing for specific imaging of adipose tissue activation, including BAT.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If FDG is used as a PET imaging agent, then glucose metabolism in activated brown fat can be detected, but specificity for BAT activation is lost because agents affecting glucose metabolism without BAT activation also increase FDG signal
Solution Approach 1:
The patent extracts the specific enzymatic pathway (dCK and dGK kinases) involved in BAT activation and develops a tracer ([18F]F-AraG) that selectively targets this pathway. This allows detection of BAT activation specifically through phosphorylation by these kinases, separating it from general glucose metabolism detection that FDG performs.
Solution Approach 2:
The patent changes the biochemical parameter being measured from general glucose metabolism (FDG) to specific phosphorylation activity by dCK/dGK kinases ([18F]F-AraG). This parameter change enables differentiation between true BAT activation and other glucose metabolic effects, achieving the desired specificity.
2Loss of information
If FDG is used to image brown fat, then increased glucose metabolism in activated brown fat can be observed, but mitochondrial changes (UCP-1 expression) cannot be imaged
Solution Approach 1:
The patent uses the phosphorylation reaction by dCK/dGK kinases as an intermediary marker that connects BAT activation to detectable signal accumulation. Since these kinases are specifically activated during BAT activation alongside mitochondrial changes, the tracer serves as an indirect but specific marker for mitochondrial activation states.
3Reliability
If non-specific glucose metabolism agents are used, then BAT activation can be detected through increased glucose metabolism, but therapeutic agent effects cannot be accurately assessed
Solution Approach 1:
The patent extracts the specific enzymatic signature (dCK/dGK phosphorylation) of true BAT activation and uses it as the detection mechanism. This extraction allows reliable differentiation between genuine BAT activation (responsive to therapeutics) and non-specific glucose metabolic effects, enabling accurate therapeutic assessment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
[18F]F-AraG provides specific and sensitive imaging of BAT activation, distinguishing between adrenergically stimulated and non-stimulated states, thereby enabling more accurate assessment of therapeutic interventions targeting BAT.
Implementation Method 1
a route of administration is selected so as to allow the compound to be phosphorylated by deoxycytosine kinase and deoxyguanosine kinase present in adipose tissue in the subject
Implementation Method 2
imaging the subject via a positron emission tomography technique, wherein detecting the presence of the compound corresponds to the presence of adipose tissues and/or the activation of adipose tissues
Data Source
AI summary
Embodiments of the present disclosure provide compositions and methods for performing positron emission tomography (PET) and, more particularly, to compositions and methods for the development and use of 18F-based PET tracers for use in selected imaging techniques such as studies of agents selected to modulate adipose tissue physiology.